Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2376 - 2400 of 15174 in total
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a...
Approved
Investigational
Matched Description: … anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and ... Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
A 4-aminoquinoquinoline compound with anti-inflammatory properties.
Approved
Investigational
Matched Categories: … artesunate and amodiaquine ... Antiparasitic Products, Insecticides and Repellents …
Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic...
Approved
Vet approved
Matched Description: … Medicine for their discovery of streptomycin and its antibacterial activity. ... [A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in ... Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and
Matched Categories: … Alimentary Tract and Metabolism ... streptomycin and isoniazid …
Edaravone is a free radical scavenger and neuroprotective agent with antioxidant properties. It has three tautomers. Edaravone works to scavenge reactive oxygen species, which have been implicated in neurological disorders, such as amyotrophic lateral sclerosis (ALS) and cerebral ischemia.[A19140,L44007,A254257] The intravenous formulation of edaravone was first approved in Japan in...
Approved
Investigational
Matched Description: … Edaravone is a free radical scavenger and neuroprotective agent with antioxidant properties. ... , which have been implicated in neurological disorders, such as amyotrophic lateral sclerosis (ALS) and ... [L44007] It was later approved for the treatment of amyotrophic lateral sclerosis (ALS) in Japan and
Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to gantenerumab, bapineuzumab and solanezumab.[A235668,A235730] Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and phase 1b clinical trial data have shown patients treated with aducanumab show a...
Approved
Investigational
Matched Description: … that targets extracellular amyloid-β plaques in the brain; similar to [gantenerumab], [bapineuzumab] and ... ] Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and ... [A235668] Based on Mini-Mental State Examination and Clinical Dementia Rating (CDR), patients taking …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects,...
Approved
Investigational
Matched Description: … It has been used in the treatment of lymphoma and leukemia. ... Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. ... Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1....
Approved
Investigational
Matched Description: … and to treat pain resulting from trigeminal neuralgia. ... Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures …
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form...
Approved
Matched Description: … Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation ... of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) ... as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting …
Matched Categories: … Netupitant and prodrug …
Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically defined as absolute eosinophil levels of 1500/mm3 or more) is associated with a spectrum of diseases, including severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). The pathogenesis of eosinophilia is complex, but IL-5 is recognized as...
Approved
Investigational
Matched Description: … Activated eosinophils further stimulate an inflammatory response and also induce tissue lesions and promote ... Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically ... spectrum of diseases, including severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Evinacumab is a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein 3 (ANGPTL3) and the first drug of its kind. The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in...
Approved
Investigational
Matched Description: … [L31838] In September and December 2023, evinacumab was also approved by Health Canada and EMA, respectively ... provides a unique and synergistic therapeutic option in the treatment of HoFH. ... a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein 3 (ANGPTL3) and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for hemorrhage and thromboembolic events, and a long-term propensity for myelofibrosis and leukemia.[A242000, A242005] Interferon alfa-2b has been used for decades to treat PV but requires frequent dosing...
Approved
Investigational
Matched Description: … and clinical trials. ... platelet/leukocyte counts, an increased risk for hemorrhage and thromboembolic events, and a long-term ... propensity for myelofibrosis and leukemia. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. All these components are produced by the fungus Claviceps purpurea and are all derivatives of the tetracyclic compound 6-methylergonovine. The derivatives of this fungus are identified to be about 350 different substances from which the components...
Approved
Matched Description: … [A32912] All these components are produced by the fungus _Claviceps purpurea_ and are all derivatives ... equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and ... [A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November …
Matched Categories: … Ergot Alkaloids and Derivatives …
A fluorinated cytosine analog that is used as an antifungal agent.
Approved
Investigational
Matched Categories: … Fluorouracil and prodrugs …
Gimeracil is an adjunct to antineoplastic therapy, used to increase the concentration and effect of the main active componets within chemotherapy regimens. Approved by the European Medicines Agency (EMA) in March 2011, Gimeracil is available in combination with DB03209 and DB09256 within the commercially available product "Teysuno". The main active...
Approved
Matched Description: … Gimeracil is an adjunct to antineoplastic therapy, used to increase the concentration and effect of the ... European Medicines Agency (EMA) in March 2011, Gimeracil is available in combination with [DB03209] and ... By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, …
2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)
Approved
Vet approved
Matched Description: … It has CNS side effects and hepatototoxic potential. ... (From Smith and Reynard, Textbook of Pharmacology, 1992, p919) ... It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. …
Matched Categories: … Imidazole and Triazole Derivatives ... Antiparasitic Products, Insecticides and Repellents …
Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. It received FDA approval in October 2019 in combination with tezacaftor and ivacaftor as the combination product TrikaftaTM. Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure...
Approved
Investigational
Matched Description: … [A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as ... Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure and ... to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and
Matched Categories: … ivacaftor, tezacaftor and elexacaftor …
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing...
Approved
Investigational
Matched Description: … for patients with metastatic bladder cancer, which demonstrates the development of more personalized and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Similar to other theophyllines, aminophylline is indicated for the treatment of lung diseases such as asthma,...
Approved
Matched Description: … blocker, and histone deacetylase activator. ... Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. ... Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor …
Matched Categories: … Xanthines and Adrenergics ... aminophylline and adrenergics …
Aluminum zirconium trichlorohydrex gly is a common active ingredient in deodorant and antiperspirant products for the over-the-counter use. It is consisted of a mixture of monomeric and polymeric Zr4+ and Al3+ complexes with hydroxide, chloride and glycine. The compound forms a colloidal plug in sweat pores, preventing sweat from leaving...
Approved
Experimental
Matched Description: … and glycine. ... It is consisted of a mixture of monomeric and polymeric Zr4+ and Al3+ complexes with hydroxide, chloride ... Aluminum zirconium trichlorohydrex gly is a common active ingredient in deodorant and antiperspirant …
An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)
Approved
Paramethadione is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.
Approved
Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT1A receptors and as an antagonist at serotonin 5-HT2A receptors. Cariprazine has been investigated in a variety of psychiatric disorders,...
Approved
Investigational
Matched Description: … [L41670] It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes ... receptors and as an antagonist at serotonin 5-HT2A receptors. ... Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in …
Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including aripiprazole, paliperidone and clozapine available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the...
Approved
Investigational
Matched Description: … Schizophrenia is a complex mental illness and impacts approximately 1% of the population. ... [L10902] Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine ... ] available for clinical use, they are generally accompanied by significant metabolic and/or neurological …
Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of macitentan. Approximately 10-15% of patients with hypertension have resistant hypertension, defined as uncontrolled high blood pressure despite the combined use of a renin-angiotensin system blocker, a calcium channel blocker,...
Approved
Investigational
Matched Description: … [A263386] and have traditionally had limited additional treatment options. ... Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension ... pressure despite the combined use of a renin-angiotensin system blocker, a calcium channel blocker, and
Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022.[L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test. IDH1 mutations are common in...
Approved
Investigational
Matched Description: … and gliomas (NCT03684811). ... Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved ... in different types of cancer, such as gliomas, AML, intrahepatic cholangiocarcinoma, chondrosarcoma, and
Displaying drugs 2376 - 2400 of 15174 in total